4.5 Article

Trajectories of Neuropsychiatric Symptoms and Cognitive Decline in Mild Cognitive Impairment

Journal

AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
Volume 24, Issue 1, Pages 70-80

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jagp.2015.06.001

Keywords

Neuropsychiatric symptoms; mild cognitive impairment; latent class analysis

Funding

  1. National Institutes of Health [R25 MH071544/MH/NIMH]
  2. University of California, San Diego, Stein Institute for Research on Aging
  3. University of Rochester CTSA award from the National Center for Advancing Translational Sciences of the National Institutes of Health [KL2 TR000095]
  4. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  5. U.S. Department of Defense ADNI (DOD) [W81XWH-12-2-0012]
  6. National Institute on Aging
  7. National Institute of Biomedical Imaging and Bioengineering
  8. Canadian Institutes of Health Research
  9. NIH [R25 MH071544/MH/NIMH]
  10. Alzheimer's Association New Investigator grant [NIRG-14-317353]
  11. AstraZeneca
  12. Avanir
  13. Baxter
  14. Biogen
  15. BMS
  16. Eisai
  17. EnVivo
  18. Genentech/Roche
  19. Janssen Alzheimer Initiative
  20. Medivation
  21. Merck
  22. Pfizer
  23. Toyama
  24. Transition Therapeutics
  25. National Institutes of Health (NIH)
  26. National Institute of Mental Health (NIMH)
  27. National Institute on Aging (NIA)
  28. Department of Defense
  29. Elan
  30. Lundbeck
  31. TransTech Pharma
  32. [Elan]

Ask authors/readers for more resources

Objective: To characterize the course of neuropsychiatric symptoms (NPS) in adults with mild cognitive impairment (MCI), and to examine baseline individual-level predictors and associated cognitive and functional outcomes. Design: A 2-year prospective cohort study. Setting: Multicenter clinical settings. Participants: Five hundred sixty individuals with MCI at baseline. Measurements: NPS severity (measured using Neuropsychiatric Inventory Questionnaire) and cognitive and functional outcomes were assessed at baseline and every 6 months thereafter. Potential individual-level predictors were collected at baseline. Results: Three latent classes of NPS courses were identified using growth mixture modeling: a stable class in which a low NPS burden remained relatively unchanged over time (N = 503, 89.8%); a worsened class in which an initially moderate NPS burden increased (N = 39, 7.0%); and an improved class in which an initially high NPS burden decreased (N = 18, 3.2%). There were no associations between class membership and baseline individual characteristics. Members of the worsened class were 1.74 times more likely to be diagnosed with incident Alzheimer disease (AD) than members of the stable class (95% confidence interval: 1.07-2.84). The worsened class also showed significantly more rapid declines in cognitive and functional outcomes than the stable class. Class membership did not predict rate of brain atrophy. Conclusions: Patients with MCI may experience different trajectories of NPS over time. Patients with worsening NPS may be at greater risk of developing AD and severe cognitive and functional impairment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available